

USANA HEALTH SCIENCES INC  
Form 10-Q  
August 12, 2015  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended July 4, 2015

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 001-35024

---

**USANA HEALTH SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Utah**  
(State or other jurisdiction  
of incorporation or organization)

**87-0500306**  
(I.R.S. Employer  
Identification No.)

---

**3838 West Parkway Blvd., Salt Lake City, Utah 84120**

(Address of principal executive offices, Zip Code)

---

**(801) 954-7100**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares outstanding of the registrant's common stock as of August 7, 2015 was 12,805,122.

---

Table of Contents

USANA HEALTH SCIENCES, INC.

FORM 10-Q

For the Quarterly Period Ended July 4, 2015

INDEX

	<b>Page</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
<u>Item 1</u>	<u>Financial Statements (unaudited)</u>
	<u>Condensed Consolidated Balance Sheets</u> 3
	<u>Condensed Consolidated Statements of Comprehensive Income</u> 4
	<u>Condensed Consolidated Statements of Stockholders' Equity</u> 5
	<u>Condensed Consolidated Statements of Cash Flows</u> 6
	<u>Notes to Condensed Consolidated Financial Statements</u> 7 15
<u>Item 2</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> 16 25
<u>Item 3</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u> 25
<u>Item 4</u>	<u>Controls and Procedures</u> 25
<b><u>PART II. OTHER INFORMATION</u></b>	
<u>Item 1</u>	<u>Legal Proceedings</u> 25
<u>Item 6</u>	<u>Exhibits</u> 26 27
<u>Signatures</u>	28

Table of Contents**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS**

(in thousands, except par value)

(unaudited)

	As of January 3, 2015	As of July 4, 2015
<b>ASSETS</b>		
Current assets		
Cash and cash equivalents	\$ 111,126	\$ 150,929
Inventories	45,248	54,022
Prepaid expenses and other current assets	34,553	39,864
Total current assets	190,927	244,815
Property and equipment, net	71,164	73,939
Goodwill	17,941	17,948
Intangible assets, net	40,952	40,763
Deferred tax assets	5,933	5,998
Other assets	23,667	25,047
	\$ 350,584	\$ 408,510
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities		
Accounts payable	\$ 7,779	\$ 9,038
Other current liabilities	100,926	103,818
Total current liabilities	108,705	112,856
Deferred tax liabilities	10,601	10,068
Other long-term liabilities	1,114	1,062
Stockholders' equity		
Common stock, \$0.001 par value; Authorized 50,000 shares, issued and outstanding 12,633 as of January 3, 2015 and 12,805 as of July 4, 2015	13	13
Additional paid-in capital	61,613	71,737

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Retained earnings	166,406	211,502
Accumulated other comprehensive income	2,132	1,272
Total stockholders' equity	230,164	284,524
	\$ 350,584	\$ 408,510

The accompanying notes are an integral part of these statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, except per share data)

(unaudited)

	Quarter Ended		Six Months Ended	
	June 28, 2014	July 4, 2015	June 28, 2014	July 4, 2015
Net sales	\$ 188,256	\$ 233,244	\$ 370,657	\$ 452,622
Cost of sales	34,865	40,089	68,693	78,453
Gross profit	153,391	193,155	301,964	374,169
Operating expenses:				
Associate incentives	81,098	101,877	159,972	203,230
Selling, general and administrative	43,206	52,505	87,783	102,380
Total operating expenses	124,304	154,382	247,755	305,610
Earnings from operations	29,087	38,773	54,209	68,559
Other income (expense):				
Interest income	215	232	427	386
Interest expense		(7)	(6)	(7)
Other, net	82	(311)	1	(297)
Other income (expense), net	297	(86)	422	82
Earnings before income taxes	29,384	38,687	54,631	68,641
Income taxes	10,083	13,271	18,793	23,545
Net earnings	\$ 19,301	\$ 25,416	\$ 35,838	\$ 45,096
Earnings per common share				
Basic	\$ 1.40	\$ 1.99	\$ 2.59	\$ 3.55
Diluted	\$ 1.36	\$ 1.92	\$ 2.50	\$ 3.43
Weighted average common shares outstanding				
Basic	13,768	12,740	13,843	12,694
Diluted	14,235	13,225	14,315	13,155
Comprehensive income:				
Net earnings	\$ 19,301	\$ 25,416	\$ 35,838	\$ 45,096

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Other comprehensive income (loss), net of tax:							
Foreign currency translation adjustment	802		(1,947)		(860)		(1,384)
Tax benefit (expense) related to foreign currency translation adjustment	(262)		744		390		524
Other comprehensive income (loss), net of tax	540		(1,203)		(470)		(860)
Comprehensive income	\$	19,841	\$	24,213	\$	35,368	\$ 44,236

The accompanying notes are an integral part of these statements.



Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY

Six Months Ended July 4, 2015

(in thousands)

(unaudited)

	Common Stock Shares	Common Stock Value	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Balance at January 3, 2015	12,633	\$ 13	\$ 61,613	\$ 166,406	\$ 2,132	\$ 230,164
Net earnings				45,096		45,096
Other comprehensive income (loss), net of tax					(860)	(860)
Equity-based compensation expense			4,388			4,388
Common stock issued under equity award plans	172					
Tax benefit from equity award activity			5,736			5,736
Balance at July 4, 2015	12,805	\$ 13	\$ 71,737	\$ 211,502	\$ 1,272	\$ 284,524

The accompanying notes are an integral part of these statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Six Months Ended	
	June 28, 2014	July 4, 2015
Cash flows from operating activities		
Net earnings	\$ 35,838	\$ 45,096
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities		
Depreciation and amortization	4,408	4,630
(Gain) loss on sale of property and equipment	16	28
Equity-based compensation expense	4,071	4,388
Excess tax benefits from equity-based payment arrangements	(3,387)	(5,736)
Deferred income taxes	(605)	(1,029)
Changes in operating assets and liabilities:		
Inventories	3,034	(9,454)
Prepaid expenses and other assets	(5,144)	(5,722)
Income tax payable related to tax benefit from equity award activity	3,387	5,736
Accounts payable	(3,085)	1,165
Other liabilities	(7,283)	7,065
Net cash provided by (used in) operating activities	31,250	46,167
Cash flows from investing activities		
Additions to notes receivable	(2,520)	(1,578)
Purchases of investment securities held-to-maturity	(3,871)	
Maturities of investment securities	9,137	
Proceeds from sale of property and equipment	8	
Purchases of property and equipment	(10,103)	(9,778)
Net cash provided by (used in) investing activities	(7,349)	(11,356)
Cash flows from financing activities		
Excess tax benefits from equity-based payment arrangements	3,387	5,736
Repurchase of common stock	(46,109)	
Net cash provided by (used in) financing activities	(42,722)	5,736
Effect of exchange rate changes on cash and cash equivalents	(255)	(744)
Net increase (decrease) in cash and cash equivalents	(19,076)	39,803
Cash and cash equivalents, beginning of period	137,343	111,126

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Cash and cash equivalents, end of period	\$	118,267	\$	150,929
Supplemental disclosures of cash flow information				
Cash paid during the period for:				
Interest	\$	6	\$	7
Income taxes		9,963		14,978
Non-cash investing activities:				
Credits on notes receivable		116		56
Accrued purchases of property and equipment		331		149
Non-cash financing activities:				
Unsettled trades for repurchase of common stock		(2,985)		

The accompanying notes are an integral part of these statements

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE A ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION**

USANA Health Sciences, Inc. develops and manufactures high-quality nutritional and personal care products that are sold internationally through a global network marketing system, which is a form of direct selling. The Consolidated Financial Statements include the accounts and operations of USANA Health Sciences, Inc. and its wholly-owned subsidiaries (collectively, the Company or USANA ) in two geographic regions: Asia Pacific, and Americas and Europe. Asia Pacific is further divided into three sub-regions: Greater China, Southeast Asia Pacific, and North Asia. Greater China includes Hong Kong, Taiwan and China; Southeast Asia Pacific includes Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand; North Asia includes Japan, and South Korea. Americas and Europe includes the United States, Canada, Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands. All intercompany accounts and transactions have been eliminated in this consolidation.

The condensed consolidated balance sheet as of January 3, 2015, derived from audited financial statements, and the unaudited interim consolidated financial information of the Company have been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission. Certain information and footnote disclosures that are normally included in financial statements that have been prepared in accordance with accounting principles generally accepted in the United States of America ( U.S. GAAP ) have been condensed or omitted pursuant to such rules and regulations. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of any contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. In the opinion of management, the accompanying interim consolidated financial information contains all adjustments, consisting of normal recurring adjustments that are necessary to state fairly the Company's financial position as of July 4, 2015 and results of operations for the quarters and six months ended June 28, 2014 and July 4, 2015.

The interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto that are included in the Company's Annual Report on Form 10-K for the year ended January 3, 2015. The results of operations for the quarter and six months ended July 4, 2015, may not be indicative of the results that may be expected for the fiscal year 2015 ending January 2, 2016.

**Recent Accounting Pronouncements**

In May 2014, the Financial Accounting Standards Board ( FASB ) issued an Accounting Standard Update ( ASU ) No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 includes a five-step process by which entities will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which an entity expects to be entitled in exchange for those goods or services. The standard also will require enhanced disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In July 2015, the FASB announced a decision to defer the

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

effective date of this ASU. ASU 2014-09 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted for annual and interim reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact ASU 2014-09 will have on its consolidated financial statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE B FAIR VALUE MEASURES

The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:

- Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.
- Level 2 inputs are from other than quoted market prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable and are used to measure fair value in situations where there is little, if any, market activity for the asset or liability at the measurement date.

As of January 3, 2015, the following financial assets and liabilities were measured at fair value on a recurring basis using the type of inputs shown:

	January 3, 2015	Level 1	Fair Value Measurements Using	
			Inputs Level 2	Level 3
Money market funds included in cash equivalents	\$ 4,833	\$ 4,833	\$	\$

	July 4, 2015	Level 1	Fair Value Measurements Using	
			Inputs Level 2	Level 3
Money market funds included in cash equivalents	\$ 20,956	\$ 20,956	\$	\$

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

There were no transfers of financial assets or liabilities between Level 1 and Level 2 inputs for the periods indicated.

The majority of the Company's non-financial assets, which include goodwill, intangible assets, and property and equipment, are not required to be carried at fair value on a recurring basis. However, if certain triggering events occur (or tested at least annually for goodwill and indefinite-lived intangibles) such that a non-financial asset is required to be evaluated for impairment, an impairment charge is recorded to reduce the carrying value to the fair value, if the carrying value exceeds the fair value. At January 3, 2015 and July 4, 2015, there were no non-financial assets measured at fair value on a non-recurring basis.

The Company's financial instruments include cash equivalents, accounts receivable, restricted cash, notes receivable, and accounts payable. The recorded values of cash equivalents, accounts receivable, restricted cash, and accounts payable approximate their fair values, based on their short-term nature. The carrying value of the notes receivable approximate fair value because the variable interest rates in the notes reflect current market rates.

Table of Contents**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(in thousands, except per share data)****(unaudited)****NOTE C INVENTORIES**

Inventories consist of the following:

	<b>January 3, 2015</b>	<b>July 4, 2015</b>
Raw materials	\$ 15,127	\$ 16,449
Work in progress	7,545	8,779
Finished goods	22,576	28,794
	<b>\$ 45,248</b>	<b>\$ 54,022</b>

**NOTE D OTHER ASSETS**

Other assets consists primarily of a secured loan to a third-party supplier of the Company's nutrition bars and land use rights related to a production facility under development in China.

The Company has extended non-revolving credit to its supplier of nutrition bars to allow them to acquire equipment that is necessary to manufacture the USANA nutrition bars. This relationship provides improved supply chain stability for USANA and creates a mutually beneficial relationship between the parties. Notes receivable are valued at their unpaid principal balance plus any accrued but unpaid interest, which approximates fair value. Interest accrues at an annual interest rate of LIBOR plus 400 basis points. The note has a maturity date of February 1, 2024 and will be repaid by a combination of cash payments and credits for the manufacture of USANA's nutrition bars. There is no prepayment penalty. Notes receivable from this supplier as of January 3, 2015, and July 4, 2015 were \$8,519 and \$9,041, respectively

This third-party supplier is considered to be a variable interest entity; however, the Company is not the primary beneficiary due to the inability to direct the activities that most significantly affect the third-party supplier's economic performance. Additionally, the Company does not absorb a majority of the third-party supplier's expected losses or returns. Consequentially, the financial information of the third-party supplier is not consolidated. The maximum exposure to loss as a result of the Company's involvement with the third-party supplier is limited to the carrying value of the note receivable due from the third-party supplier.



## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

The Company is building a state-of-the-art manufacturing and production facility in China, which is expected to become operational in early 2016. As part of this project, land use rights totaling \$7,378, and \$7,382 as of January 3, 2015 and July 4, 2015, respectively, have been purchased and are being amortized over 50 years.

### **NOTE E LINE OF CREDIT**

The Company has a \$75,000 line of credit with Bank of America. Interest is computed at the bank's Prime Rate or LIBOR, adjusted by features specified in the Credit Agreement. The collateral for this line of credit is the pledge of the capital stock of certain subsidiaries of the Company, set forth in a separate pledge agreement with the bank. Part of the credit agreement is that any existing bank guarantees are considered a reduction of the overall availability of credit and part of the covenant calculation. This resulted in a \$4,575, and \$4,296 reduction in the available borrowing limit as of January 3, 2015 and July 4, 2015, respectively, due to existing normal course of business guarantees in certain markets. The Credit Agreement contains restrictive covenants based on adjusted EBITDA and a debt coverage ratio.

There was no outstanding debt on this line of credit at January 3, 2015 or at July 4, 2015. The Company will be required to pay any balance on this line of credit in full at the time of maturity in April 2016 unless the line of credit is replaced or terms are renegotiated.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE F CONTINGENCIES**

The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company records a liability when a particular contingency is probable and estimable. The Company has not accrued for any contingency at July 4, 2015 as the Company does not consider any contingency to be probable nor estimable. The Company faces contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While complete assurance cannot be given to the outcome of these proceedings, management does not currently believe that any of these matters, individually or in the aggregate, will have a material adverse effect on our financial condition, liquidity or results of operations.

On August 7, 2014, a purported shareholder derivative lawsuit was filed in the Third Judicial District Court of Salt Lake County, State of Utah, against certain of the Company's directors and officers. The derivative complaint, which also names USANA as a nominal defendant but is asserted on USANA's behalf, contains claims of breach of fiduciary duty, waste of corporate assets and unjust enrichment against the defendant directors and officers in connection with certain equity awards granted by the Compensation Committee of the Company's Board of Directors in February 2014. In October 2014, the Company filed a motion to dismiss the complaint and, in March 2015, the court granted that motion and dismissed the complaint without prejudice. In May 2015, the plaintiffs filed an appeal with the Utah Supreme Court. The Company believes the claims in the complaint are without merit and intends to continue to vigorously defend the suit. In the opinion of management, and based upon advice of counsel, the likelihood of an adverse outcome against the Company in this matter is remote. As such, management believes that the ultimate outcome of this lawsuit will not have a material impact on the Company's financial position or results of operations.

Table of Contents**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(in thousands, except per share data)****(unaudited)****NOTE G EQUITY BASED COMPENSATION**

The Company utilizes a share-based compensation plan, which is more fully described in Note K to the Consolidated Financial Statements in Form 10-K for the year ended January 3, 2015. The description provided applies to the Company's 2006 Plan as well as its recently adopted 2015 Equity Incentive Award Plan (the 2015 Plan). The Company adopted the 2015 Plan to replace the (2006 Plan), which is set to expire in April of 2016. As of July 4, 2015, the Company had not issued awards under the 2015 Plan. The maximum number of shares of common stock available for issuance under the 2015 Plan is 5,000.

Equity-based compensation expense for the quarters ended June 28, 2014, and July 4, 2015, was \$2,235, and \$2,178 respectively. The related tax benefit for these periods was \$743, and \$742, respectively. Expense for the six months ended June 28, 2014 and July 4, 2015, was \$4,071 and \$4,388, respectively. The related tax benefit for these periods was \$1,359 and \$1,483, respectively.

The following table shows the remaining unrecognized compensation expense on a pre-tax basis for all types of unvested equity awards outstanding as of July 4, 2015. This table does not include an estimate for future grants that may be issued.

2015	\$	3,919
2016		7,214
2017		4,843
2018		1,756
2019+		582
	\$	18,314

The cost above is expected to be recognized over a weighted-average period of 1.8 years.

The Company uses the Black-Scholes option pricing model to estimate the fair value of its equity awards. The weighted-average fair value of stock-settled stock appreciation rights that were granted during the six months ended June 28, 2014, and July 4, 2015, was \$17.73 and \$31.80, respectively. Following is a table that includes the weighted-average assumptions that the Company used to calculate fair value of equity awards that were granted during the periods indicated.

	Six Months Ended	
	June 28, 2014	July 4, 2015
Expected volatility (1)	39.9%	40.6%
Risk-free interest rate (2)	1.2%	1.1%
Expected life (3)	3.54 yrs.	3.33 yrs.
Expected dividend yield (4)	0.0%	0.0%
Weighted-average exercise price (5)	\$ 57.62	\$ 105.27

---

(1) The Company utilizes historical volatility of the trading price of its common stock.

(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.

(3) Depending upon the terms of the award, one of two methods will be used to calculate expected life:

(i) a weighted-average that includes historical settlement data of the Company's equity awards and a hypothetical holding period, or (ii) the simplified method.

(4) The Company historically has not paid and currently has no plan to pay dividends.

(5) Exercise price is the closing price of the Company's common stock on the date of grant.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE G EQUITY BASED COMPENSATION - CONTINUED

A summary of the Company's stock option and stock-settled stock appreciation right activity is as follows:

	Shares	Weighted-average exercise price	Weighted-average remaining contractual term	Aggregate intrinsic value*
Outstanding at January 3, 2015	1,555	\$ 49.20	2.9	\$ 82,564
Granted	130	105.27		
Exercised	(250)	37.26		
Forfeited	(18)	43.83		
Expired				
Outstanding at July 4, 2015	1,417	\$ 56.52	2.8	\$ 120,766
Exercisable at July 4, 2015	58	\$ 39.33	1.9	\$ 5,902

\*Aggregate intrinsic value is defined as the difference between the current market value at the reporting date (the closing price of the Company's common stock on the last trading day of the period) and the exercise price of awards that were in-the-money. The closing price of the Company's common stock at January 3, 2015, and July 4, 2015, was \$102.28 and \$141.74, respectively.

The total intrinsic value of stock-settled stock appreciation rights exercised during the six months ended June 28, 2014, and July 4, 2015, was \$14,404 and \$21,036, respectively.

The total fair value of equity awards that vested during the six months ended June 28, 2014, and July 4, 2015, was \$3,506 and \$3,775, respectively. This total fair value includes equity-based awards issued in the form of stock-settled stock appreciation rights.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

**NOTE H COMMON STOCK AND EARNINGS PER SHARE**

Basic earnings per share are based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic earnings per share based on the time they were outstanding in any period. Diluted earnings per common share are based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted earnings per share calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised.

The following is a reconciliation of the numerator and denominator used to calculate basic earnings per share and diluted earnings per share for the periods indicated:

	Quarter Ended		Six Months Ended	
	June 28, 2014	July 4, 2015	June 28, 2014	July 4, 2015
Net earnings available to common shareholders	\$ 19,301	\$ 25,416	\$ 35,838	\$ 45,096
Weighted average common shares outstanding - basic	13,768	12,740	13,843	12,694
Dilutive effect of in-the-money equity awards	467	485	472	461
Weighted average common shares outstanding - diluted	14,235	13,225	14,315	13,155
Earnings per common share from net earnings - basic	\$ 1.40	\$ 1.99	\$ 2.59	\$ 3.55
Earnings per common share from net earnings - diluted	\$ 1.36	\$ 1.92	\$ 2.50	\$ 3.43

Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be anti-dilutive:

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

	Quarter Ended		Six Months Ended	
	June 28, 2014	July 4, 2015	June 28, 2014	July 4, 2015
	383	102	328	113

Table of Contents**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(in thousands, except per share data)****(unaudited)****NOTE I SEGMENT INFORMATION**

USANA operates as a direct selling company that develops, manufactures, and distributes high-quality nutritional and personal care products that are sold through a global network marketing system of independent distributors ( Associates ). As such, management aggregates its operating segments into one reportable segment as management believes that the Company's segments exhibit similar long-term financial performance and have similar economic characteristics. Performance for a region or market is evaluated based on sales. No single Associate accounted for 10% or more of net sales for the periods presented. The table below summarizes the approximate percentage of total product revenue that has been contributed by the Company's nutritional and personal care products for the periods indicated.

	Quarter Ended		Six Months Ended	
	June 28, 2014	July 4, 2015	June 28, 2014	July 4, 2015
USANA® Nutritionals	78%	81%	79%	81%
USANA Foods	14%	12%	13%	12%
Sensé beautiful science®	7%	6%	7%	6%

Selected financial information for the Company is presented for two geographic regions: Americas and Europe, and Asia Pacific, with three sub-regions under Asia Pacific. Individual markets are categorized into these regions as follows:

- Asia Pacific
  - Greater China – Hong Kong, Taiwan and China(1)
  - Southeast Asia Pacific – Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand
  - North Asia – Japan and South Korea
- Americas and Europe – United States, Canada, Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands.



---

(1) The Company's business in China is that of BabyCare, its wholly-owned subsidiary.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE I SEGMENT INFORMATION - CONTINUED

*Selected Financial Information*

Financial information by geographic region is presented for the periods indicated below:

	Quarter Ended		Six Months Ended	
	June 28, 2014	July 4, 2015	June 28, 2014	July 4, 2015
Net Sales to External Customers				
Asia Pacific				
Greater China	\$ 74,091	\$ 112,333	\$ 144,938	\$ 213,619
Southeast Asia Pacific	42,689	46,033	83,137	91,372
North Asia	7,815	10,346	15,106	19,575
Asia Pacific Total	124,595	168,712	243,181	324,566
Americas and Europe	63,661	64,532	127,476	128,056
Consolidated Total	\$ 188,256	\$ 233,244	\$ 370,657	\$ 452,622

The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived assets, respectively:

	Quarter Ended		Six Months Ended	
	June 28, 2014	July 4, 2015	June 28, 2014	July 4, 2015
Net sales:				
China	\$ 51,223	\$ 94,476	\$ 89,983	\$ 178,286
United States	\$ 35,570	\$ 34,842	\$ 73,183	\$ 71,144
Hong Kong	N/A	N/A	\$ 38,926	N/A

	As of	
	January 3, 2015	July 4, 2015
Long-lived Assets:		
China	\$ 81,704	\$ 82,194
United States	\$ 53,322	\$ 58,059

Table of Contents

**Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion and analysis of USANA's financial condition and results of operations is presented in six sections:

- Overview
- Customers
- Current Focus and Recent Developments
- Results of Operations
- Liquidity and Capital Resources
- Forward-Looking Statements and Certain Risks

This discussion and analysis should be read in conjunction with the Unaudited Condensed Consolidated Financial Statements and Notes thereto that are contained in this quarterly report, as well as Management's Discussion and Analysis of Financial Condition and Results of Operations that are included in our Annual Report on Form 10-K for the year ended January 3, 2015, and our other filings, including Current Reports on Form 8-K, that have been filed with the Securities and Exchange Commission (SEC) through the date of this report.

**Overview**

We develop and manufacture high-quality, science-based nutritional and personal care products that are distributed internationally through a network marketing system, which is a form of direct selling. We have chosen this distribution method as we believe it is more conducive to meeting our vision as a company, which is improving the overall health and nutrition of individuals and families around the world. Our customer base comprises two types of customers: Associates and Preferred Customers. Associates share in our company vision by acting as independent distributors of our products in addition to purchasing our products for their personal use. Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. As of July 4, 2015, we had approximately 397,000 active Associates and approximately 91,000 active Preferred Customers worldwide. For purposes of this report, we only count as active customers those Associates and Preferred Customers who have purchased from us at any time during the most recent three-month period.

We have ongoing operations in the following markets, which are grouped and presented as follows:

- Asia Pacific

- Greater China Hong Kong, Taiwan, and China(1)
- Southeast Asia Pacific Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand
- North Asia Japan and South Korea
- Americas and Europe United States, Canada, Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands

---

(1) Our business in China is that of BabyCare, our wholly-owned subsidiary.

Our primary product lines consist of USANA® Nutritionals, USANA Foods, and Sensé beautiful science® (Sensé), which is our line of personal care products. The USANA Nutritionals product line is further categorized into two separate classifications: Essentials and Optimizers. The following tables summarize the approximate percentage of total product revenue that has been contributed by our major product lines and our top-selling products for the current and prior-year periods as indicated:

Table of Contents

<b>Product Line</b>	<b>Six months ended</b>	
	<b>June 28, 2014</b>	<b>July 4, 2015</b>
<b>USANA® Nutritionals</b>		
Essentials	25%	23%
Optimizers	54%	58%
USANA Foods	13%	12%
Sensé beautiful science®	7%	6%
All Other	1%	1%
<b>Key Product</b>		
USANA® Essentials	16%	15%
Proflavanol®	13%	13%
BiOmega-3	9%	12%

We believe that our ability to attract and retain Associates and Preferred Customers to sell and consume our products is positively influenced by a number of factors, some of which include: the general public's heightened awareness and understanding of the connection between diet and long-term health, and the growing desire for a secondary source of income and small business ownership.

We believe that our high-quality products and our financially rewarding Associate Compensation Plan are the key components to attracting and retaining Associates. We periodically make changes to our Compensation Plan in an effort to ensure that our plan is among the most rewarding in the industry, to encourage behavior that we believe leads to a successful business for our Associates, and to ensure that our plan provides us with leverage to grow sales and earnings.

To further support our Associates in building their businesses, we sponsor meetings and events throughout the year, which offer information about our products and our network marketing system. These meetings are designed to assist Associates in their business development and to provide a forum for interaction with our Associate leaders and members of our management team. We also provide low cost sales tools, including online sales, business management, and training tools, which we believe are an integral part of building and maintaining a successful home-based business for our Associates. Although we provide training and sales tools, we ultimately rely on our Associates to sell our products, attract new customers to purchase our products, and educate and train new Associates.

Because we have operations in multiple markets, with sales and expenses being generated and incurred in multiple currencies, our reported U.S. dollar sales and earnings can be significantly affected by fluctuations in currency exchange rates. In general, our operating results are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar. During the six months ended July 4, 2015, net sales outside of the United States represented 84.3% of consolidated net sales. In our net sales discussions that follow, we approximate the impact of currency fluctuations on net sales by translating current year sales at the average exchange rates in effect during the comparable periods of the prior year.

**Customers**

Because we sell our products exclusively to a customer base of independent Associates and Preferred Customers, to increase net sales we must either increase the number or the productivity of our Associates and Preferred Customers. Increasing the productivity of our Associates and

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Preferred Customers has not been our primary focus. Rather, we seek to increase the number of Associates and Preferred Customers who use our products. We believe this focus is more consistent with our vision of improving the overall health and nutrition of individuals and families around the world. Sales to Associates account for the majority of our product sales, representing approximately 91.8% of product sales during the six months ended July 4, 2015. The remainder of our sales are to Preferred Customers. Increases or decreases in product sales are typically the result of variations in the volume of

Table of Contents

product sold relating to fluctuations in the number of active Associates and Preferred Customers purchasing our products. The number of active Associates and Preferred Customers is, therefore, used by management as a key non-financial measure.

The tables below summarize the changes in our active customer base by geographic region. These numbers have been rounded to the nearest thousand as of the dates indicated.

Active Associates By Region						
	As of June 28, 2014		As of July 4, 2015		Change from Prior Year	Percent Change
Asia Pacific:						
Greater China	125,000	44.1%	216,000	54.4%	91,000	72.8%
Southeast Asia Pacific	67,000	23.7%	79,000	19.9%	12,000	17.9%
North Asia	9,000	3.2%	13,000	3.3%	4,000	44.4%
Asia Pacific Total	201,000	71.0%	308,000	77.6%	107,000	53.2%
Americas and Europe	82,000	29.0%	89,000	22.4%	7,000	8.5%
	283,000	100.0%	397,000	100.0%	114,000	40.3%

Preferred Customers By Region						
	As of June 28, 2014		As of July 4, 2015		Change from Prior Year	Percent Change
Asia Pacific:						
Greater China	3,000	3.8%	4,000	4.4%	1,000	33.3%
Southeast Asia Pacific	11,000	13.9%	12,000	13.2%	1,000	9.1%
North Asia	5,000	6.4%	9,000	9.9%	4,000	80.0%
Asia Pacific Total	19,000	24.1%	25,000	27.5%	6,000	31.6%
Americas and Europe	60,000	75.9%	66,000	72.5%	6,000	10.0%
	79,000	100.0%	91,000	100.0%	12,000	15.2%

**Current Focus and Recent Developments**

Our primary objective is to increase the number of Associates and Preferred Customers who use our products throughout the world. We have several strategies in place to support this objective, including:

- Our focus on personalizing our customer's overall experience with USANA, which includes personalizing our product offering, Associate Compensation Plan, and our online business environment;
- Our investment in increasing our brand recognition, which includes our relationship as a Trusted Partner and Sponsor of *The Dr. Oz Show*, our sponsorship of the U.S. Ski Team, and our partnership with the Women's Tennis



Association; to make it easier for our Associates to talk about USANA with potential customers;

- Our development and offering of market-specific incentives and promotions for our Associates to incent sales and customer growth around the world; and
- Our continued focus on international expansion as we prepare to commence operations in Indonesia later this year. Indonesia will be USANA's 20<sup>th</sup> market and represents a promising growth opportunity for us.

Table of Contents**Results of Operations***Summary of Financial Results*

Net sales for the second quarter of 2015 increased 23.9% to \$233.2 million, an increase of \$45.0 million, compared with the second quarter of 2014. This increase was driven by higher product sales volume resulting primarily from strong Associate growth in our Asia Pacific region. In addition to the general momentum of our business in many of our markets, the utilization of market-specific promotions and incentives has helped generate further growth. Unfavorable changes in currency exchange rates reduced net sales for the quarter by \$9.7 million.

Net earnings for the second quarter of 2015 increased 31.7% to \$25.4 million, an increase of \$6.1 million, compared with the second quarter of 2014. The increase in net earnings was driven by higher net sales and improved gross margins.

**Quarters Ended June 28, 2014 and July 4, 2015***Net Sales*

The following table summarizes the changes in our net sales by geographic region for the quarters ended as of the dates indicated:

	Net Sales by Region (in thousands) Quarter Ended				Change from prior year	Percent change	Currency impact on sales	Percent change excluding currency impact
	June 28, 2014		July 4, 2015					
Asia Pacific								
Greater China	\$ 74,091	39.4%	\$ 112,333	48.2%	\$ 38,242	51.6%	\$ 281	51.2%
Southeast Asia								
Pacific	42,689	22.7%	46,033	19.7%	3,344	7.8%	(4,512)	18.4%
North Asia	7,815	4.1%	10,346	4.4%	2,531	32.4%	(814)	42.8%
Asia Pacific Total	124,595	66.2%	168,712	72.3%	44,117	35.4%	(5,045)	39.5%
Americas and Europe	63,661	33.8%	64,532	27.7%	871	1.4%	(4,620)	8.6%
	\$ 188,256	100.0%	\$ 233,244	100.0%	\$ 44,988	23.9%	\$ (9,665)	29.0%

*Asia Pacific:* The increase in net sales in Greater China continues to be driven by growth in China, where local currency net sales increased 83.6% and the number of active Associates increased 98%. Sales in China benefited from continued momentum following promotions run the past few quarters, and from \$5.0 million in revenue that was

deferred during the previous quarter in connection with price increases. Although sales in Greater China were reduced by another year-over-year decline in Hong Kong, which we anticipate will be the case through the remainder of 2015, on a consecutive quarter basis local currency sales in Hong Kong increased 6.5%.

The increase in local currency net sales in Southeast Asia Pacific was driven by growth in the number of active Associates purchasing our products in every market within the region. Although local currency sales growth was modestly slower in the Philippines compared to what we have seen over the last several quarters, we saw stronger growth in other markets within this region.

The increase in local currency net sales in North Asia continues to be driven by growth in South Korea, where local currency net sales increased 50.7% and Associates increased 57.1%.

Table of Contents

*Americas and Europe:* The increase in local currency net sales in this region was again driven by growth in Canada and Mexico, where local currency net sales increased 22.2% and 20.6%, respectively, Associates increased 12.0% and 20.0%, respectively, and Preferred Customers increased 25.0% and 33.3%, respectively. Sales in the United States declined 2.0%.

*Gross Profit*

Gross profit increased to 82.8% of net sales for the second quarter of 2015, from 81.5% in the prior year. This improvement can be attributed to a favorable shift in sales mix by market and by modest product price adjustments that we implemented during the first and second quarters of 2015. These improvements were partially offset by the negative impact from a strengthening of the US dollar.

*Associate Incentives*

Associate incentives were 43.7% of net sales for the second quarter of 2015, compared with 43.1% in the second quarter of 2014. This increase can be attributed to higher spending on contests and promotions, and a higher relative payout under our Matching Bonus program. These increases were slightly offset by our annual price adjustment.

*Selling, General and Administrative Expenses*

Selling, general and administrative expense relative to net sales decreased to 22.5% during the second quarter of 2015, compared with 23.0% in the second quarter of 2014. This decrease can be attributed to higher net sales, partially offset by timing of costs associated with our Asia Pacific Convention, which was held during the second quarter of 2015 and in the first quarter in 2014.

*Income Taxes*

Our effective income tax rate for the second quarter of 2015 was consistent with the prior year quarter at 34.3%. Both periods are comparable, receiving tax benefits from the U.S. manufacturing deduction and favorable foreign tax rates.

*Diluted Earnings Per Share*

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Diluted earnings per share increased 41.2% in the second quarter of 2015 when compared with the prior year quarter. This increase was the result of higher net earnings as discussed above, combined with a 7.1% reduction in diluted shares outstanding.

Table of Contents**Six Months Ended June 28, 2014 and July 4, 2015***Net Sales*

The following table summarizes the changes in our net sales by geographic region for the periods ended as of the dates indicated:

	Net Sales by Region (in thousands)				Change from prior year	Percent change	Currency impact on sales	Percent change excluding currency impact
	Six Months Ended June 28, 2014		Six Months Ended July 4, 2015					
Asia Pacific								
Greater China	\$ 144,938	39.1%	\$ 213,619	47.2%	\$ 68,681	47.4%	\$ (1,765)	48.6%
Southeast Asia								
Pacific	83,137	22.4%	91,372	20.2%	8,235	9.9%	(7,549)	19.0%
North Asia	15,106	4.1%	19,575	4.3%	4,469	29.6%	(1,224)	37.7%
Asia Pacific Total	243,181	65.6%	324,566	71.7%	81,385	33.5%	(10,538)	37.8%
Americas and Europe	127,476	34.4%	128,056	28.3%	580	0.5%	(8,292)	7.0%
	\$ 370,657	100.0%	\$ 452,622	100.0%	\$ 81,965	22.1%	\$ (18,830)	27.2%

*Asia Pacific:* The increase in net sales in Greater China included a 99.5% increase in local currency net sales in China. Net sales and Associate growth in China during the first six months of 2015 benefited from: (i) momentum created from a short-term incentive promotions that we offered the past few quarters, (ii) a more favorable operating environment for the Company during the first quarter of 2015 when compared with the previous year, and (iii) higher-than-anticipated incremental sales of approximately \$17.0 million that occurred following the announcement of our 2015 price adjustments in this market. Net sales growth in Greater China was partially offset by a continued year-over-year decline in Hong Kong sales and Associates, which we anticipate to continue through the remainder of 2015. Notably, however, sales in this market increased on a consecutive quarter basis.

The increase in local currency net sales in Southeast Asia Pacific was driven by double-digit sales growth from every market during the first six months of 2015, with the exception of Singapore. This increase was the result of growth in the average number of active Associates purchasing our products during the first six months of the year.

The increase in local currency net sales in North Asia continues to be driven by growth in South Korea, where local currency net sales increased 48.9%.

*Americas and Europe:* The increase in local currency net sales in this region was driven by growth in Canada and Mexico, where local currency net sales increased 18.5% and 20.5%, respectively. Sales in the United States declined 2.8%.

*Gross Profit*

Gross profit increased to 82.7% of net sales for the first six months of 2015, from 81.5% in the comparable prior year period. This improvement can be attributed to a favorable shift in sales mix by market and by modest price adjustments that we implemented during the first half of the year. These improvements were partially offset by the negative impact from a strengthening of the US dollar.

Table of Contents

*Associate Incentives*

Associate incentives were 44.9% of net sales for the first six months of 2015, compared with 43.2% in the comparable prior year period. This increase can primarily be attributed to increased spending on contests and promotions, particularly in the first quarter of the year, and also to a higher payout under our Matching Bonus program. We continue to expect that Associate incentives relative to net sales will range between 44.0% and 44.5% for the remainder of the year.

*Selling, General and Administrative Expenses*

Selling, general and administrative expense relative to net sales decreased to 22.6% during the first six months of 2015, compared with 23.7% in the comparable prior year period. This decrease can be primarily attributed to higher net sales.

*Income Taxes*

Our effective income tax rate for the first six months of 2015 was 34.3%, which was similar to our effective tax rate for the first six months of 2014 at 34.4%. Both periods benefited from the U.S. manufacturing deduction, however, this benefit has increased slightly over that in 2014.

*Diluted Earnings Per Share*

Diluted earnings per share increased 37.2% in the first six months of 2015 when compared with the prior year period. This increase was the result of higher net earnings as discussed above, combined with an 8.1% reduction in diluted shares outstanding.

**Liquidity and Capital Resources**

We have historically met our working capital and capital expenditure requirements by using both net cash flow from operations and by drawing from our line of credit. Our principal source of liquidity is our operating cash flow. Although we are required to maintain cash deposits with banks in certain of our markets, there are currently no material restrictions on our ability to transfer and remit funds among our international markets. The hypothetical repatriation of \$12.3 million that relates to earnings considered indefinitely reinvested in certain of our markets at July 4, 2015, would result in a tax liability to the Company of approximately \$1.5 million.

We have historically generated positive cash flow due to our strong operating margins. Net cash flow from operating activities totaled \$46.2 million in the first six months of 2015, compared with \$31.3 million in the prior year period. Items positively affecting cash flow from



## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

operations on a year-over-year basis include: (i) an increase in accrued incentives and deferred revenue resulting from higher sales, (ii) an increase in net earnings, and (iii) an increase in accounts payable in the current year, compared with a decrease in the prior year, due to timing of invoices and payments. These improvements were partially offset by an increase in inventory in the current year due to: (i) higher inventory demands in China, where sales have increased significantly and where we are preparing to transition to our new facility, and (ii) clearing inventory into several markets that had been held up from west coast port congestion caused by the dockworker strikes that took place earlier this year.

Cash and cash equivalents increased to \$150.9 million at July 4, 2015, from \$111.1 million at January 3, 2015. Of the \$150.9 million held at July 4, 2015, \$56.2 million was held in the United States and \$94.7 million was held by international subsidiaries. Of the \$111.1 million cash and cash equivalents held at January 3, 2015, \$37.8 million was held in the United States and \$73.3 million was held by international subsidiaries. Net working capital increased to \$132.0 million at July 4, 2015, from \$82.2 million at January 3, 2015.

We continue to expect that our new state-of-the-art manufacturing and production facility in China will become operational in early 2016. Of the anticipated \$40 million investment for this project, we have incurred \$20.6 million through the end of the second quarter of 2015, \$1.9 million of which was incurred during the first six months of 2015.

Table of Contents

We have extended non-revolving credit to the supplier of our nutrition bars to allow this supplier to modify its facility and acquire the necessary equipment to manufacture our bars. Notes receivable from this supplier as of July 4, 2015 and January 3, 2015, were \$9.0 million and \$8.5 million, respectively, and are included as non-current other assets on the balance sheet.

*Line of credit*

We have a long-standing relationship with Bank of America. We currently maintain a \$75.0 million credit facility pursuant to a credit agreement with the bank, which expires in April 2016. Bank guarantees are considered a reduction of the overall availability of credit. As of July 4, 2015, such normal course of business bank guarantees reduced our available borrowing limit by \$4.3 million. We did not otherwise draw on this line of credit at any time during the first six months of 2015, and, as of July 4, 2015, there was no actual outstanding balance on our line of credit.

The agreement for this credit facility contains restrictive covenants, which require us to maintain a consolidated rolling four-quarter adjusted earnings before interest, taxes, depreciation and amortization ( adjusted EBITDA ) equal to or greater than \$60.0 million, and a ratio of consolidated funded debt to adjusted EBITDA of 2.0 to 1.0 at the end of each quarter. The adjusted EBITDA under this agreement is modified for certain non-cash expenses. As of July 4, 2015, we were in compliance with these covenants. Management is not aware of any issues currently impacting Bank of America's ability to honor their commitment to extend credit under this facility.

*Share repurchase*

We have a share repurchase plan that has been ongoing since the fourth quarter of 2000. The objective of this plan is to return value to our shareholders. Our Board of Directors has periodically approved additional dollar amounts for share repurchases under that plan. Share repurchases are made from time-to-time, in the open market, through block trades or otherwise, and are based on market conditions, the level of our cash balances, general business opportunities, and other factors. We did not repurchase any shares of common stock during the six months ended July 4, 2015. As of July 4, 2015, the remaining approved repurchase amount under the plan was \$61.2 million. There currently is no expiration date on the remaining approved repurchase amount and no requirement for future share repurchases.

*Summary*

We believe that current cash balances, future cash provided by operations, and amounts available under our line of credit will be sufficient to cover our operating and capital needs in the ordinary course of business for the foreseeable future. If we experience an adverse operating environment or unanticipated and unusual capital expenditure requirements, additional financing may be required. No assurance can be given, however, that additional financing, if required, would be available at all or on favorable terms. We might also require or seek additional financing for the purpose of expanding into new markets, growing our existing markets, or for other reasons. Such financing may include the use of additional debt or the sale of additional equity securities. Any financing which involves the sale of equity securities or instruments that are convertible into equity securities could result in immediate and possibly significant dilution to our existing shareholders.

**Forward-Looking Statements and Certain Risks**

The statements contained in this report that are not purely historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934 (the Exchange Act ). These statements represent our expectations, hopes, beliefs, anticipations, commitments, intentions, and strategies regarding the future. They may be identified by the use of words or phrases such as believes, expects, anticipates, should, plans, estimates, and potential, among others. Forward-looking statements include, but are not limited to, statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue, and expense levels in the future and the sufficiency of our existing assets to fund our future operations and capital spending needs. Readers are cautioned that actual results could differ materially from the anticipated results or other expectations that are expressed in these forward-looking statements for the reasons that are detailed in our most recent Annual

Table of Contents

Report on Form 10-K. The fact that some of these risk factors may be the same or similar to those in our past SEC reports means only that the risks are present in multiple periods. We believe that many of the risks detailed here and in our other SEC filings are part of doing business in the industry in which we operate and will likely be present in all periods reported. The fact that certain risks are common in the industry does not lessen their significance. The forward-looking statements contained in this report are made as of the date of this report, and we assume no obligation to update them or to update the reasons why our actual results could differ from those that we have projected. Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:

- Our ability to attract and maintain a sufficient number of Associates;
- Our dependence upon a network marketing system to distribute our products and the activities of our independent Associates;
- The integration of BabyCare's operations and expansion of our business in China through BabyCare;
- Unanticipated effects of changes to our Compensation Plan;
- Our planned expansion into international markets, including delays in commencement of sales or product offerings in any new market, delays in compliance with local marketing or other regulatory requirements, or changes in target markets;
- General economic conditions, both domestically and internationally;
- Potential political events, natural disasters, or other events that may negatively affect economic conditions;
- Potential effects of adverse publicity regarding the Company, nutritional supplements, or the network marketing industry;
- Reliance on key management personnel;

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

- Extensive government regulation of the Company's products, manufacturing, and network marketing system;
- Potential inability to sustain or manage growth, including the failure to continue to develop new products;
- An increase in the amount of Associate incentives;
- Our reliance on the use of information technology;
- The effects of competition from new and established network and direct selling organizations in our key markets;
- The adverse effect of the loss of a high-level sponsoring Associate, together with a group of leading Associates, in that person's downline;
- The loss of product market share or Associates to competitors;
- Potential adverse effects of customs, duties, taxation, and transfer pricing regulations, including regulations governing distinctions between and Company responsibilities to employees and independent contractors;
- The fluctuation in the value of foreign currencies against the U.S. dollar;
- Our reliance on outside suppliers for raw materials and certain manufactured items;
- Shortages of raw materials that we use in certain of our products;
- Significant price increases of our key raw materials;
- Product liability claims and other risks that may arise with our manufacturing activity;

- Intellectual property risks;
- Liability claims that may arise with our Athlete Guarantee program;
- Continued compliance with debt covenants;
- Disruptions to shipping channels that are used to distribute our products to international warehouses;
- The introduction of new laws or changes to existing laws, both domestically and internationally; and

Table of Contents

- The outcome of regulatory and litigation matters.

**Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

There have been no material changes to information presented from that presented for the year ended January 3, 2015.

**Item 4. CONTROLS AND PROCEDURES**

**Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods that are specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of July 4, 2015.

**Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting that occurred during the quarter ended July 4, 2015, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II. OTHER INFORMATION**

**Item 1. LEGAL PROCEEDINGS**

In August 2014, a purported shareholder derivative lawsuit was filed in the Third Judicial District Court of Salt Lake County, State of Utah (*James Robert Rawcliffe v. Robert Anciaux, et al.*) against certain of our directors and officers. The derivative complaint, which also names USANA as a nominal defendant but is asserted on USANA's behalf, contains claims of breach of fiduciary duty, waste of corporate assets and unjust enrichment against the defendant directors and officers in connection with certain equity awards granted by the Compensation Committee of the Company's Board of Directors in February 2014. In October 2014, we filed a motion to dismiss the complaint and, in March 2015, the court granted that motion and dismissed the complaint without prejudice. On May 6, 2015, the plaintiffs filed an appeal with the Utah Supreme Court. We believe that the claims in the complaint are without merit and will continue to vigorously defend this suit. We continue to believe, based on information currently available, that the final outcome of this suit will not have a material adverse effect on the Company's business, results of operations or consolidated financial position.



Table of Contents

**Item 6. EXHIBITS**

Exhibit Number	Description
3.1	Amended and Restated Articles of Incorporation (Incorporated by reference to Report on Form 8-K, filed April 25, 2006)
3.2	Bylaws (Incorporated by reference to Report on Form 8-K, filed April 25, 2006)
4.1	Specimen Stock Certificate for Common Stock, no par value (Incorporated by reference to Registration Statement on Form 10, File No. 0-21116, effective April 16, 1993)
10.1	Credit Agreement, dated June 16, 2004, by and between Bank of America, N.A. and USANA Health Sciences, Inc. (Incorporated by reference to Report on Form 10-Q for the period ended July 3, 2004)
10.2	Amendment dated May 17, 2006 to Credit Agreement dated June 16, 2004 (Incorporated by reference to Report on Form 10-Q for the period ended September 30, 2006)
10.3	Amendment dated April 24, 2007 to Credit Agreement dated June 16, 2004 (Incorporated by reference to Report on Form 10-Q for the period ended March 31, 2007)
10.4	USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 25, 2006)*
10.5	Form of Stock Option Agreement for award of non-statutory stock options to employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.6	Form of Stock Option Agreement for award of non-statutory stock options to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.7	Form of Incentive Stock Option Agreement for employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.8	Form of Stock-Settled Stock Appreciation Rights Award Agreement for employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.9	Form of Stock-Settled Stock Appreciation Rights Award Agreement for directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.10	Form of Deferred Stock Unit Award Agreement for grants of deferred stock units to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.11	Form of Indemnification Agreement between the Company and its directors (Incorporated by reference to Report on Form 8-K, filed May 24, 2006)*
10.12	Form of Indemnification Agreement between the Company and certain of its officers (Incorporated by reference to Report on Form 8-K, filed May 24, 2006)*
10.13	Share Purchase Agreement, dated as of August 16, 2010, among USANA Health Sciences, Inc., Petlane, Inc., Yaolan Ltd., and BabyCare Holdings Ltd. (Incorporated by Reference to Report on Form 8-K, filed August 16, 2010)

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

10.14 Amended and Restated Credit Agreement, dated as of April 27, 2011 (Incorporated by reference to Report on Form 8-K, filed April 28, 2011)

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

### Table of Contents

10.15	Form of Executive Confidentiality, Non-Disclosure and Non-Solicitation Agreement (Incorporated by reference to Quarterly Report on Form 10-Q for the period ended October 1, 2011, filed November 9, 2011)*
10.16	Separation and Release of Claims Agreement dated as of December 21, 2012 by and between USANA Health Sciences, Inc. and Roy Truett (incorporated by reference to Report on Form 8-K/A, filed December 26, 2012)*
10.17	Amendment to Confidentiality, Non-Disclosure and Non-Solicitation Agreement dated as of December 21, 2012 by and between USANA Health Sciences, Inc. and Roy Truett (incorporated by reference to Report on Form 8-K/A, filed December 26, 2012)*
10.18	Amendment to Amended and Restated Credit Agreement, dated as of July 18, 2013 (Incorporated by reference to Report on Form 8-K, filed July 23, 2013)
10.19	USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)*
10.20	Form of Stock-Settled Stock Appreciation Rights Award Agreement for employees under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)*
10.21	Form of Stock-Settled Stock Appreciation Rights Award Agreement for non-employee directors under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)*
10.22	Form of Restricted Stock Unit Award Agreement for employees under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)*
10.23	Form of Restricted Stock Unit Award Agreement for non-employee directors under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)*
10.24	Form of Deferred Stock Unit Award Agreement for grants of deferred stock units to non-employee director under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)*
31.1	Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
32.2	Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

---

\* Denotes a management contract or compensatory plan or arrangement.



Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

USANA HEALTH SCIENCES, INC.

Date: August 12, 2015

/s/ Paul A. Jones  
Paul A. Jones  
Chief Financial Officer

(Principal Financial and Accounting Officer)